Home » Eisai’s Dacogen Patient Card Called Misleading
Eisai’s Dacogen Patient Card Called Misleading
November 20, 2009
The patient profile card for Eisai’s Dacogen presents misleading claims that minimize the product’s risks and overstates its efficacy in treating
myelodysplastic syndromes that affect the bone marrow, the FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) says.